BridgeMD
New treatment option for Bladder Cancer
Official title Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer
ClinicalTrials.gov ID: NCT05067101
What this study is testing
- What it's testing
- Bladder cancer is a common malignant tumor of the urinary system, radical resection plus urinary diversion is the first choice of treatment for muscle invasive bladder cancer. Urinary diversion of surgical options related to patient'survival and quality of life.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older, men only
You may be able to join if
- Adult males aged 20 and above and healthy volunteers are not accepted;
- Bladder carcinoma in situ、T1G3 tumor、muscle invasive bladder cancer with clinical stage of cT2-T3N0M0 (If the clinical staging before neoadjuvant...
- Recurrent bladder cancer: recurrent NMIBC after treatment and Carcinoma in situ that does not respond to BCG vaccine treatment.
- ECOG score is 0 or 1.
- Voluntarily signed the informed consent.
You likely can't join if
- Preoperative serum creatinine more than 2.26mg/dl Or 200μmol/L.
- Cancer invaded prostate or urethral (confirmed by the pathology).
- Patients with distant metastasis.
- Abnormal PSA level, or suspected patients with unconfirmed prostate cancer .
- A history of other malignant tumors within three years.
- sigmoid chronic inflammation, like ulcerative colitis or intestinal tuberculosis, and so on.
See the full eligibility criteria
- Adult males aged 20 and above and healthy volunteers are not accepted;
- Bladder carcinoma in situ、T1G3 tumor、muscle invasive bladder cancer with clinical stage of cT2-T3N0M0 (If the clinical staging before neoadjuvant therapy meets the , patients who have decreased to below cT2 after...
- Recurrent bladder cancer: recurrent NMIBC after treatment and Carcinoma in situ that does not respond to BCG vaccine treatment.
- ECOG score is 0 or 1.
- Voluntarily signed the informed consent.
- Preoperative serum creatinine more than 2.26mg/dl Or 200μmol/L.
- Cancer invaded prostate or urethral (confirmed by the pathology).
- Patients with distant metastasis.
- Abnormal PSA level, or suspected patients with unconfirmed prostate cancer .
- A history of other malignant tumors within three years.
- sigmoid chronic inflammation, like ulcerative colitis or intestinal tuberculosis, and so on.
- Severe cardiopulmonary and liver dysfunction, combined with other serious diseases
- Other conditions that have been approved by a urologist for not suitable for neobladder surgery.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 20 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.